In reply to Michael Klemba's letter (1), we investigated the cellular location of the PfA-M1 aminopeptidase by transfecting Plasmodium falciparum malaria with a GFP-PfA-M1 conjugate and by probing parasite-infected erythrocytes with antibodies prepared against the recombinant protein; these antibodies should bind to native full-length protease (2) . Consistent with published studies (3), we observed reactivity in the cytosolic compartment only.
Using a substrate specific for this enzyme (Arg-NHMec), we showed that recombinant PfA-M1, as well extracts of the malaria parasite, exhibited similar pH profiles with an optimum at pH 7.0. Neither recombinant nor native material functioned below pH 6.0. It is unlikely that PfA-M1 could function within the digestive vacuole (DV), which is maintained at pH 5.5. These data are consistent with a cytosolic function.
Florent and colleagues (3, 4) showed that the 122-kDa PfA-M1 is a transmembrane protein that is processed within the malaria cell to release soluble 96-and 68-kDa cytosolic forms. We suggest that that the membrane form of PfA-M1 may lie attached to the DV membrane with the catalytic ectodomain orientated toward the cytosolic side ready for proteolytic release. This would locate the enzyme in prime position to target substrates transported out of the DV.
Our ectodomain structure contains the complete architecture of the catalytic site capable of binding both substrates and inhibitors (2) . Thus, it is unlikely that the N-terminal portion of PfA-M1 influences activity. This recombinant domain has been used to identify new lead compounds from chemical libraries that could guide the development of a novel class of antimalarial drugs (see http://pubchem.ncbi.nlm.nih.gov/assay/ assay.cgi?aidϭ1445). 
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